Compare Global X NASDAQ 100 Covered Call ETF (QYLD) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X NASDAQ 100 Covered Call ETF vs Zoetis Inc — how do they compare? Global X NASDAQ 100 Covered Call ETF trades at $18.69 (market cap $8.49B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 3.6× Global X NASDAQ 100 Covered Call ETF's market cap, and Zoetis Inc pays a 2.9% dividend while Global X NASDAQ 100 Covered Call ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X NASDAQ 100 Covered Call ETF for 51 Days and Zoetis Inc for 70 Days on average.
| QYLD | ZTS | |
|---|---|---|
Market Cap | $8.49B | $30.20B |
Volume | 2,913,938 | 6,175,327 |
Sector | Income / Options Overlay | Health |
52-Week High | $18.68 | $147.53 |
52-Week Low | $16.70 | $69.09 |
Typical Hold Time | 51 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QYLD trades at $18.69, showing minimal daily movement with a 0.05% gain. The ETF maintains a consistent monthly dividend payout of $0.18, providing an attractive yield for income-focused investors. Technical indicators present a mixed picture with an overall bullish signal from moving averages but bearish momentum from oscillators, while RSI levels suggest potential overbought conditions. Recent news highlights QYLD's role as a covered call ETF generating income through Nasdaq 100 options strategies.
The outlook for QYLD remains focused on income generation rather than capital appreciation, with the covered call strategy capping upside potential during market rallies. Key risks include declining option premiums, principal erosion over time, and tax treatment uncertainties. Investors should weigh the high monthly yield against the trade-off of limited participation in Nasdaq 100 growth, making it suitable for income needs but less ideal for long-term capital growth objectives.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
